{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:00:23Z","timestamp":1715986823983},"reference-count":32,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T00:00:00Z","timestamp":1295827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:p>Intermittent or pulsatile dopamine\u2010receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long\u2010term levodopa therapy of Parkinson\u2019s disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine\u2010receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half\u2010lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini\u2010pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol\u2010<jats:italic>O\u2010<\/jats:italic>methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long\u2010term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once\u2010daily prolonged\u2010release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once\u2010daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2010.03326.x","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T10:27:43Z","timestamp":1295864863000},"page":"3-10","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged\u2010release"],"prefix":"10.1111","volume":"18","author":[{"given":"O.","family":"Rascol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,24]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0222"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21060"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22022"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.13.1653"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10609"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23143"},{"key":"e_1_2_9_8_2","unstructured":"SchapiraAH AlbrechtS BaroneP et\u00a0al.Immediate vs. delayed\u2010start pramipexole in early Parkinson\u2019s disease: the PROUD study.XVII WFN World Congress on Parkinson\u2019s Disease and Related Disorders. Miami Beach FL USA 2010: Poster."},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809335"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20602"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20041"},{"issue":"2","key":"e_1_2_9_12_2","first-page":"S32","article-title":"Problems with long\u2010term levodopa therapy for Parkinson\u2019s disease","volume":"17","author":"Marsden CD","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70068-7"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2471"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(09)70005-7"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130207"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20317"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22060"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00004"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.7.1044"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20724"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.5.573"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000149637.70961.4C"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22112"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20898"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70225-X"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-0027-8"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.10.018"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23317"},{"key":"e_1_2_9_32_2","unstructured":"SchapiraAH BaroneP HauserRA et\u00a0al.Efficacy and safety of pramipexole extended\u2010release for advanced Parkinson\u2019s disease.Movement Disorder Society 13th International Congress. Paris France 2009: Poster We\u2010199."},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23262"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2010.03326.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2010.03326.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T17:57:38Z","timestamp":1694455058000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2010.03326.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,24]]},"references-count":32,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1468-1331.2010.03326.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03326.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,24]]},"assertion":[{"value":"2011-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}